Udo Hoffmann, Michael T Lu, Borek Foldyna, Markella V Zanni, Julia Karady, Jana Taron, Bingxue K Zhai, Tricia Burdo, Kathleen V Fitch, Emma M Kileel, Kenneth Williams, Carl J Fichtenbaum, Edgar T Overton, Carlos Malvestutto, Judith Aberg, Judith Currier, Craig A Sponseller, Kathleen Melbourne, Michelle Floris-Moore, Cornelius Van Dam, Michael C Keefer, Susan L Koletar, Pamela S Douglas, Heather Ribaudo, Thomas Mayrhofer, Steven K Grinspoon
Importance: Cardiovascular disease (CVD) is increased among people with HIV (PWH), but little is known regarding the prevalence and extent of coronary artery disease (CAD) and associated biological factors in PWH with low to moderate traditional CVD risk. Objectives: To determine unique factors associated with CVD in PWH and to assess CAD by coronary computed tomography angiography (CTA) and critical pathways of arterial inflammation and immune activation. Design, Setting, and Participants: This cohort study among male and female PWH, aged 40 to 75 years, without known CVD, receiving stable antiretroviral therapy, and with low to moderate atherosclerotic cardiovascular disease (ASCVD) risk according to the 2013 American College of Cardiology/American Heart Association pooled cohort equation, was part of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), a large, ongoing primary prevention trial of statin therapy among PWH conducted at 31 US sites...
June 1, 2021: JAMA Network Open